Answers are grounded in this paper and cite their sources.
The biopharmaceutical manufacturing sector is rapidly gearing up production capacity to satisfy the steadily escalating global demand for complex biologics to combat a number of treatable illnesses. Frequently, the biotherapeutics in demand are too complicated to be chemically synthesized and thus are beyond the reach of traditional pharmaceutical approaches. To effectively address this issue, these products must be developed and produced using viable and robust biological systems.
No takes yet. Share an insight, caveat, or question.
Birse et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: